| __timestamp | BioMarin Pharmaceutical Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 10337679 |
| Thursday, January 1, 2015 | 402271000 | 18187286 |
| Friday, January 1, 2016 | 476593000 | 24758063 |
| Sunday, January 1, 2017 | 554336000 | 23666957 |
| Monday, January 1, 2018 | 604353000 | 30099855 |
| Tuesday, January 1, 2019 | 680924000 | 64947625 |
| Wednesday, January 1, 2020 | 737669000 | 186363444 |
| Friday, January 1, 2021 | 759375000 | 272611040 |
| Saturday, January 1, 2022 | 854009000 | 358782000 |
| Sunday, January 1, 2023 | 937300000 | 409864000 |
Unleashing insights
In the competitive world of biopharmaceuticals, managing operational costs is crucial. This chart compares the Selling, General, and Administrative (SG&A) expenses of Intra-Cellular Therapies, Inc. and BioMarin Pharmaceutical Inc. from 2014 to 2023. Over this period, BioMarin's SG&A expenses have consistently outpaced those of Intra-Cellular Therapies, reflecting its larger scale and broader market reach. In 2023, BioMarin's expenses were approximately 2.3 times higher than Intra-Cellular's, highlighting its expansive operational footprint. Notably, Intra-Cellular Therapies has shown a significant upward trend, with expenses increasing nearly 40-fold since 2014, indicating rapid growth and expansion. This data provides a fascinating insight into how these companies allocate resources to support their strategic objectives, with BioMarin maintaining a steady increase and Intra-Cellular Therapies experiencing a more dramatic rise.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and BioMarin Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Bio-Techne Corporation
Intra-Cellular Therapies, Inc. and TG Therapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Intra-Cellular Therapies, Inc. vs Verona Pharma plc
Intra-Cellular Therapies, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Geron Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Verona Pharma plc
BioMarin Pharmaceutical Inc. and Jazz Pharmaceuticals plc: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Alkermes plc
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Catalyst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Mesoblast Limited